Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (541-550 of 759) with videos related to

Pageof 76
Sort By:
Blood Cancer Journal|February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
Kidney International|November 12, 2021
The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosisSamar M Said, Alejandro Best Rocha, Anthony M Valeri, et al.
American Journal of Hematology|January 2, 2023
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survivalCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Blood|August 16, 2017
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosisYi L Hwa, Rahma Warsame, Morie A Gertz, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Mayo Clinic Proceedings|May 10, 2017
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic ExperienceTaxiarchis V Kourelis, Robert A Kyle, David Dingli, et al.
American Journal of Hematology|June 25, 2016
Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluationYi L Hwa, Shaji K Kumar, Morie A Gertz, et al.
American Journal of Hematology|March 15, 2016
Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experienceTaxiarchis V Kourelis, Francis K Buadi, Shaji K Kumar, et al.
Pageof 76

Showing results (541-550 of 759) with videos related to

Sort By:
Pageof 76
Blood Cancer Journal|February 11, 2022
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
Kidney International|November 12, 2021
The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosisSamar M Said, Alejandro Best Rocha, Anthony M Valeri, et al.
American Journal of Hematology|January 2, 2023
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survivalCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Blood|August 16, 2017
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosisYi L Hwa, Rahma Warsame, Morie A Gertz, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Mayo Clinic Proceedings|May 10, 2017
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic ExperienceTaxiarchis V Kourelis, Robert A Kyle, David Dingli, et al.
American Journal of Hematology|June 25, 2016
Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluationYi L Hwa, Shaji K Kumar, Morie A Gertz, et al.
American Journal of Hematology|March 15, 2016
Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experienceTaxiarchis V Kourelis, Francis K Buadi, Shaji K Kumar, et al.
Pageof 76